Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trial

Himanshu Pophale, Monica Gupta, Lily Llorens, Piotr Iwanowski, Ranjeet Gutte, Rajesh Chavan, Anasuya Patel, Harsha Agrawal, Snehal Palwe, Prashant Joshi, Hariharan Periasamy, Mahesh Patel, Balaji Veeraraghavan, Sachin Bhagwat

Open source

DOI: 10.1016/j.lansea.2025.100666
Published: 2025-10
Container: The Lancet Regional Health - Southeast Asia
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lansea.2025.100666,
  title = {Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trial},
  author = {Himanshu Pophale and Monica Gupta and Lily Llorens and Piotr Iwanowski and Ranjeet Gutte and Rajesh Chavan and Anasuya Patel and Harsha Agrawal and Snehal Palwe and Prashant Joshi and Hariharan Periasamy and Mahesh Patel and Balaji Veeraraghavan and Sachin Bhagwat},
  year = {2025},
  journal = {The Lancet Regional Health - Southeast Asia},
  doi = {10.1016/j.lansea.2025.100666},
  url = {https://doi.org/10.1016/j.lansea.2025.100666}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trial
AU  - Himanshu Pophale
AU  - Monica Gupta
AU  - Lily Llorens
AU  - Piotr Iwanowski
AU  - Ranjeet Gutte
AU  - Rajesh Chavan
AU  - Anasuya Patel
AU  - Harsha Agrawal
AU  - Snehal Palwe
AU  - Prashant Joshi
AU  - Hariharan Periasamy
AU  - Mahesh Patel
AU  - Balaji Veeraraghavan
AU  - Sachin Bhagwat
PY  - 2025
JO  - The Lancet Regional Health - Southeast Asia
DO  - 10.1016/j.lansea.2025.100666
UR  - https://doi.org/10.1016/j.lansea.2025.100666
ER  -

APA

Pophale, H., Gupta, M., Llorens, L., Iwanowski, P., Gutte, R., Chavan, R., Patel, A., Agrawal, H., Palwe, S., Joshi, P., Periasamy, H., Patel, M., Veeraraghavan, B., & Bhagwat, S. (2025). Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trial. The Lancet Regional Health - Southeast Asia. https://doi.org/10.1016/j.lansea.2025.100666

Source records

crossref · retrieved 2026-09-25T23:48:36.448Z